UniProt ID | MAX_HUMAN | |
---|---|---|
UniProt AC | P61244 | |
Protein Name | Protein max {ECO:0000305} | |
Gene Name | MAX {ECO:0000312|HGNC:HGNC:6913} | |
Organism | Homo sapiens (Human). | |
Sequence Length | 160 | |
Subcellular Localization | Nucleus. Cell projection, dendrite. | |
Protein Description | Transcription regulator. Forms a sequence-specific DNA-binding protein complex with MYC or MAD which recognizes the core sequence 5'-CAC[GA]TG-3'. The MYC:MAX complex is a transcriptional activator, whereas the MAD:MAX complex is a repressor. May repress transcription via the recruitment of a chromatin remodeling complex containing H3 'Lys-9' histone methyltransferase activity. Represses MYC transcriptional activity from E-box elements.. | |
Protein Sequence | MSDNDDIEVESDEEQPRFQSAADKRAHHNALERKRRDHIKDSFHSLRDSVPSLQGEKASRAQILDKATEYIQYMRRKNHTHQQDIDDLKRQNALLEQQVRALEKARSSAQLQTNYPSSDNSLYTNAKGSTISAFDGGSDSSSESEPEEPQSRKKLRMEAS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Phosphorylation | ------MSDNDDIEV ------CCCCCCCCC | 45.16 | 28355574 | |
2 | Acetylation | ------MSDNDDIEV ------CCCCCCCCC | 45.16 | 19413330 | |
2 (in isoform 2) | Acetylation | - | 45.16 | 21406692 | |
2 (in isoform 2) | Phosphorylation | - | 45.16 | 28355574 | |
11 | Phosphorylation | NDDIEVESDEEQPRF CCCCCCCCCCCCHHH | 56.34 | 29255136 | |
11 (in isoform 2) | Phosphorylation | - | 56.34 | 22167270 | |
20 | Phosphorylation | EEQPRFQSAADKRAH CCCHHHHHHHHHHHH | 23.78 | 27486199 | |
24 | Acetylation | RFQSAADKRAHHNAL HHHHHHHHHHHHHHH | 46.92 | 25953088 | |
24 | Ubiquitination | RFQSAADKRAHHNAL HHHHHHHHHHHHHHH | 46.92 | - | |
40 | Acetylation | RKRRDHIKDSFHSLR HHHHHHHHHHHHHHH | 43.85 | 26051181 | |
40 | Ubiquitination | RKRRDHIKDSFHSLR HHHHHHHHHHHHHHH | 43.85 | - | |
42 | Phosphorylation | RRDHIKDSFHSLRDS HHHHHHHHHHHHHHC | 21.62 | 24532841 | |
45 | Phosphorylation | HIKDSFHSLRDSVPS HHHHHHHHHHHCCHH | 24.08 | 28555341 | |
49 | Phosphorylation | SFHSLRDSVPSLQGE HHHHHHHCCHHHCCC | 29.50 | 7479834 | |
57 | Ubiquitination | VPSLQGEKASRAQIL CHHHCCCHHHHHHHH | 59.49 | - | |
66 | Acetylation | SRAQILDKATEYIQY HHHHHHHHHHHHHHH | 54.48 | 17217336 | |
68 | Phosphorylation | AQILDKATEYIQYMR HHHHHHHHHHHHHHH | 34.75 | - | |
70 | Phosphorylation | ILDKATEYIQYMRRK HHHHHHHHHHHHHHC | 6.75 | 22817900 | |
73 | Phosphorylation | KATEYIQYMRRKNHT HHHHHHHHHHHCCCC | 5.30 | 23532336 | |
75 | Methylation | TEYIQYMRRKNHTHQ HHHHHHHHHCCCCCC | 41.30 | 115482711 | |
89 | Methylation | QQDIDDLKRQNALLE CCCHHHHHHHHHHHH | 59.96 | 115972851 | |
89 | Ubiquitination | QQDIDDLKRQNALLE CCCHHHHHHHHHHHH | 59.96 | - | |
107 | Phosphorylation | RALEKARSSAQLQTN HHHHHHHHHHHHCCC | 34.58 | 30576142 | |
108 | Phosphorylation | ALEKARSSAQLQTNY HHHHHHHHHHHCCCC | 17.93 | 30576142 | |
115 | Phosphorylation | SAQLQTNYPSSDNSL HHHHCCCCCCCCCCC | 14.10 | 22817900 | |
117 | Phosphorylation | QLQTNYPSSDNSLYT HHCCCCCCCCCCCEE | 39.71 | 29978859 | |
118 | Phosphorylation | LQTNYPSSDNSLYTN HCCCCCCCCCCCEEC | 35.99 | 25159151 | |
121 | Phosphorylation | NYPSSDNSLYTNAKG CCCCCCCCCEECCCC | 27.95 | 28796482 | |
123 | Phosphorylation | PSSDNSLYTNAKGST CCCCCCCEECCCCCE | 9.58 | 28796482 | |
124 | Phosphorylation | SSDNSLYTNAKGSTI CCCCCCEECCCCCEE | 33.71 | 28796482 | |
129 | Phosphorylation | LYTNAKGSTISAFDG CEECCCCCEEEECCC | 23.12 | 26552605 | |
130 | Phosphorylation | YTNAKGSTISAFDGG EECCCCCEEEECCCC | 27.85 | 26552605 | |
132 | Phosphorylation | NAKGSTISAFDGGSD CCCCCEEEECCCCCC | 23.99 | 26552605 | |
138 | Phosphorylation | ISAFDGGSDSSSESE EEECCCCCCCCCCCC | 39.59 | 20363803 | |
140 | Phosphorylation | AFDGGSDSSSESEPE ECCCCCCCCCCCCCC | 37.14 | 17081983 | |
141 | Phosphorylation | FDGGSDSSSESEPEE CCCCCCCCCCCCCCC | 43.02 | 17081983 | |
142 | Phosphorylation | DGGSDSSSESEPEEP CCCCCCCCCCCCCCC | 49.44 | 25137130 | |
144 | Phosphorylation | GSDSSSESEPEEPQS CCCCCCCCCCCCCHH | 61.47 | 28355574 | |
151 | Phosphorylation | SEPEEPQSRKKLRME CCCCCCHHHHHHHHH | 57.70 | 27251275 | |
153 | Acetylation | PEEPQSRKKLRMEAS CCCCHHHHHHHHHCC | 62.50 | 17217336 | |
154 | Acetylation | EEPQSRKKLRMEAS- CCCHHHHHHHHHCC- | 39.97 | 17217336 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
2 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
2 | S | Phosphorylation | Kinase | CK2-FAMILY | - | GPS |
2 | S | Phosphorylation | Kinase | CK2_GROUP | - | PhosphoELM |
11 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
11 | S | Phosphorylation | Kinase | CK2-FAMILY | - | GPS |
11 | S | Phosphorylation | Kinase | CK2_GROUP | - | PhosphoELM |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of MAX_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of MAX_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Max is acetylated by p300 at several nuclear localization residues."; Faiola F., Wu Y.-T., Pan S., Zhang K., Farina A., Martinez E.; Biochem. J. 403:397-407(2007). Cited for: ACETYLATION AT LYS-66; LYS-153 AND LYS-154, AND MUTAGENESIS OF LYS-66;LYS-153 AND LYS-154. | |
Phosphorylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2 AND SER-11, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2 AND SER-11, AND MASSSPECTROMETRY. | |
"Immunoaffinity profiling of tyrosine phosphorylation in cancercells."; Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,Zha X.-M., Polakiewicz R.D., Comb M.J.; Nat. Biotechnol. 23:94-101(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-123, AND MASSSPECTROMETRY. |